A Phase 1 interventional study of Zanaflex Capsules and Zanaflex Capsules in Spasticity Due to Cerebral Palsy, sponsored by Acorda Therapeutics. Terminated at 1 site in United States. Open to participants aged 2 Years to 16 Years. Per ClinicalTrials.gov, last updated 2013-06-17.
Sponsored by Acorda Therapeutics · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 372 studies in Cerebral Palsy with a site in United States — 75 open to participants now, 103 under way, none of them phase 3. Cerebral Palsy · United States.
Among the 372 studies in Cerebral Palsy with a site in United States, this one is the 223rd largest by enrollment of the 296 interventional ones that give a count, is one of 9 that started in 2011, is one of 25 in phase 1, and was the 71st registered.
1,939 studies on the registry are indexed under Cerebral Palsy; 457 are open to participants now.
Browse Cerebral Palsy studies →75 of the 372 studies in Cerebral Palsy with a site in United States are open now. Recruiting first, the newest first:
The Foundation for Orthopaedics and Regenerative Medicine · Sites in United States, Greece
University of Washington · Sites in United States
Ages 4–65
University of Wisconsin, Madison · Sites in United States
Ages 7–17
Columbia University · Sites in United States
Ages 18–80
Martin Piazza · Sites in United States
Ages 3–14
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 269 Cerebral Palsy studies recruiting now, 27 (10%) set no upper age limit and 234 (87%) stop at 75 or younger; 254 take children under 18; 52 take healthy volunteers.
This study: 2 Years to 16 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
372 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 36 · Phase 2 31 · Phase 3 18 · Phase 4 7
First in 1987; this study’s year is marked. 9 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 34 across 1,432 interventional studies indexed under Cerebral Palsy.
Median enrollment 25 across the 296 interventional studies, 61 across the 71 observational. Of the 226 that completed or were terminated, 83 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 372 have an industry lead sponsor. The 10 most frequent:
Acorda Therapeutics is the lead sponsor of 38 studies on the registry; none are open to participants now.
Acorda Therapeutics has 2 studies filed under Cerebral Palsy — fewer than ten, so there is no comparison to draw.
25 of the studies in Cerebral Palsy with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07516067Martin PiazzaSpinal Cord Stimulation for Children With Cerebral Palsy | 2026-11 |
| NCT04630392Georgia State UniversityEffects of Treadmill Training and Whole-body Vibration in Children With Cerebral Palsy | 2026-11-20 |
| NCT05339932Grand Valley State UniversityGrand Valley State University (GVSU) Skills on Wheels | 2026-11-30 |
| NCT06377085Shirley Ryan AbilityLabRepurposing 5-Azacytidine for the Treatment of Muscle Contractures in Children With Cerebral Palsy | 2026-12 |
| NCT04897347Teachers College, Columbia UniversityRobotic TruST-Postural Intervention for Children With Cerebral Palsy | 2026-12 |
Add all 25 to your calendar (.ics) → With an account.
Among the 372 studies in Cerebral Palsy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Single-Dose, Phase 1b, Multicenter, Open-Label Study to Assess the Pharmacokinetics, Safety and Tolerability, and Pharmacodynamics of Tizanidine at 4 Different Oral Dose Levels in Pediatric Subjects 2 to 16 Years Old With Mild to Moderate Spasticity Due to Cerebral Palsy.
Evaluation of the study's progress after the amendment remained challenging with continued pre-screen failures noted in areas of Botox injection inclusion; family participation refusal / disinterest and gastric or jejunostomy tube placement. A third protocol amendment to improve enrollment was discussed with the Investigators who did not believe further amendment would overcome the barriers expressed by parents that would subject their children to an intense study time commitment without direct benefit. The investigative sites were notified that the study was closed to enrollment March 27, 2012.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Zanaflex Capsules
Drug: Zanaflex Capsules
Drug: Zanaflex Capsules
Drug: Zanaflex Capsules
0.025 mg/kg
Also known as: tizanidine HCI (hydrochloride)
0.05 mg/kg
Also known as: tizanidine HCI (hydrochloride)
0.075 mg/kg
Also known as: tizanidine HCI (hydrochloride)
0.1 mg/kg
Also known as: tizanidine HCI (hydrochloride)
Pharmacokinetic (PK) Parameter AUC0-8 (Area Under the Concentration-time Curve From Time 0 to 8 Hours) of a Single Dose of Tizanidine at 4 Different Dose Levels in Children and Adolescents With Cerebral Palsy and Mild to Moderate Spasticity.
Baseline: immediately before the standardized meal (i.e., before administration of tizanidine) on dosing day 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours after administration of tizanidine PK parameters will be derived by using WinNonlin Pro (version 5.0.1 or later, Pharsight Corp).
Time frame: Baseline and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours
Pharmacokinetic (PK) Parameter Cmax (Maximum Observed Drug Concentration in Plasma) of a Single Dose of Tizanidine at 4 Different Dose Levels in Children and Adolescents With Cerebral Palsy and Mild to Moderate Spasticity.
Baseline: immediately before the standardized meal (i.e., before administration of tizanidine) on dosing day 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours after administration of tizanidine PK parameters will be derived by using WinNonlin Pro (version 5.0.1 or later, Pharsight Corp).
Time frame: Baseline and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours
| Milestone | Dose Level 1 | Dose Level 2 | Dose Level 3 | Dose Level 4 |
|---|---|---|---|---|
| Started | 8 | 2 | 0 | 0 |
| Completed | 7 | 2 | 0 | 0 |
| Not completed | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 |
Baseline: immediately before the standardized meal (i.e., before administration of tizanidine) on dosing day 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours after administration of tizanidine PK parameters will be derived by using WinNonlin Pro (version 5.0.1 or later, Pharsight Corp).
| hour*nanogram/mililiter | Dose Level 1 | Dose Level 2 | Dose Level 3 | Dose Level 4 |
|---|---|---|---|---|
| Pharmacokinetic (PK) Parameter AUC0-8 (Area Under the Concentration-time Curve From Time 0 to 8 Hours) of a Single Dose of Tizanidine at 4 Different Dose Levels in Children and Adolescents With Cerebral Palsy and Mild to Moderate Spasticity. | 5.60 ± 1.79 | 6.11 ± 1.29 | — | — |
Baseline: immediately before the standardized meal (i.e., before administration of tizanidine) on dosing day 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours after administration of tizanidine PK parameters will be derived by using WinNonlin Pro (version 5.0.1 or later, Pharsight Corp).
| nanogram/mililiter | Dose Level 1 | Dose Level 2 | Dose Level 3 | Dose Level 4 |
|---|---|---|---|---|
| Pharmacokinetic (PK) Parameter Cmax (Maximum Observed Drug Concentration in Plasma) of a Single Dose of Tizanidine at 4 Different Dose Levels in Children and Adolescents With Cerebral Palsy and Mild to Moderate Spasticity. | 1.87 ± 0.60 | 5.29 ± 0.05 | — | — |
Collected over Up to 30 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dose Level 1 | — | 0/8 (0%) | 1/8 (12.5%) |
| Dose Level 2 | — | 0/2 (0%) | 2/2 (100%) |
| Event | Dose Level 1 | Dose Level 2 |
|---|---|---|
| SomnolenceNervous system disorders | 1/8 | 2/2 |
| Musculoskeletal StiffnessMusculoskeletal and connective tissue disorders | 0/8 | 1/2 |
| Age, Customized(participants) | Dose Level 1 | Dose Level 2 | Total |
|---|---|---|---|
| 2-3 years | 3 | 0 | 3 |
| 4-5 years | 1 | 0 | 1 |
| 6-12 years | 3 | 2 | 5 |
| 13-16 years | 1 | 0 | 1 |
| Sex: Female, Male(Participants) | Dose Level 1 | Dose Level 2 | Total |
|---|---|---|---|
| Female | 5 | 1 | 6 |
| Male | 3 | 1 | 4 |
| Ethnicity (NIH/OMB)(Participants) | Dose Level 1 | Dose Level 2 | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 8 | 2 | 10 |
| Unknown or Not Reported | 0 | 0 | 0 |
The record gives a start of May 2011, a primary completion of Mar 2012 and a completion of Mar 2012. It does not say whether these dates are actual or estimated.
Results were first posted in May 2013, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tizanidine